Sökning: WFRF:(Mikko S) > Avidity-Based Affin...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04021naa a2200469 4500 | |
001 | oai:research.chalmers.se:6ff6cf34-0b06-4749-af36-b370c32f1690 | |
003 | SwePub | |
008 | 200124s2019 | |||||||||||000 ||eng| | |
024 | 7 | a https://doi.org/10.1021/acssensors.9b013922 DOI |
024 | 7 | a https://research.chalmers.se/publication/5150772 URI |
040 | a (SwePub)cth | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Akkilic, Namiku AstraZeneca AB4 aut |
245 | 1 0 | a Avidity-Based Affinity Enhancement Using Nanoliposome-Amplified SPR Sensing Enables Low Picomolar Detection of Biologically Active Neuregulin 1 |
264 | c 2019-11-14 | |
264 | 1 | b American Chemical Society (ACS),c 2019 |
520 | a Biomarkers serve as indicators of disease progression or therapeutic response of an medical intervention, and means for enabling a reliable and sensitive biomarker detection are therefore vital in clinical settings. Most biosensor assays require high-affinity interactions in combination with an enzyme or fluorescent tag to enable detection and frequently employ extensive washing procedures prior to signal readout. Attempts to overcome this limitation by using natural biological partners tend to be demanding, because their very low affinity is frequently not compatible with the need of reaching low limits of detection (LODs), especially for circulating biomarkers that possess short half-lives. To address these challenges, we developed a label-free surface plasmon resonance (SPR) platform for the detection of neuregulin 1 (NRG1) using ErbB4-modified liposomes offering both signal amplification and affinity enhancement via functional multivalent interactions. Through the functional avidity interaction between NRG1 and ErbB4, an LOD of 3.5 picomolar was reached, which is about 60-fold higher than traditional SPR and miniaturized immunoassays. The biosensor displays also an 8-fold higher sensitivity when compared with a single-molecule immunoassay employing the natural binding partner rather than a high-affinity antibody as one of the interaction partners. In fact, the liposome-induced avidity between NRG1 and ErbB4 offered an LOD that was comparable to that obtained using a high-affinity antibody and enabled detection of NRG1 in plasma with a LOD of 36 pM. Employing the liposome-enhanced platform in conjunction with a low-affinity biomarker receptor thus enables the assessment of the functional state of the biomarker at competitive LODs and eliminates the need for high-affinity antibodies. | |
650 | 7 | a NATURVETENSKAPx Kemix Analytisk kemi0 (SwePub)104012 hsv//swe |
650 | 7 | a NATURAL SCIENCESx Chemical Sciencesx Analytical Chemistry0 (SwePub)104012 hsv//eng |
650 | 7 | a NATURVETENSKAPx Fysikx Annan fysik0 (SwePub)103992 hsv//swe |
650 | 7 | a NATURAL SCIENCESx Physical Sciencesx Other Physics Topics0 (SwePub)103992 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Läkemedelskemi0 (SwePub)301032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Medicinal Chemistry0 (SwePub)301032 hsv//eng |
653 | a neuregulin | |
653 | a biomarker | |
653 | a avidity | |
653 | a biosensing | |
653 | a liposome | |
653 | a receptor | |
653 | a surface plasmon resonance | |
700 | 1 | a Liljeblad, Mathiasu AstraZeneca AB4 aut |
700 | 1 | a Blaho, Stefanu AstraZeneca AB4 aut |
700 | 1 | a Hölttä, Mikkou AstraZeneca AB4 aut |
700 | 1 | a Höök, Fredrik,d 1966u Chalmers tekniska högskola,Chalmers University of Technology4 aut0 (Swepub:cth)fredrikh |
700 | 1 | a Geschwindner, S.u AstraZeneca AB4 aut |
710 | 2 | a AstraZeneca ABb Chalmers tekniska högskola4 org |
773 | 0 | t ACS Sensorsd : American Chemical Society (ACS)g 4:12, s. 3166-3174q 4:12<3166-3174x 2379-3694 |
856 | 4 8 | u https://doi.org/10.1021/acssensors.9b01392 |
856 | 4 8 | u https://research.chalmers.se/publication/515077 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy